Oxcarbazepine (All indications) - Medication and Pregnancy KB

Oxcarbazepine (All indications)

Congenital heart defects

R analysis

id	Study	Lib. in paper	Exposition period	Study type All studies Case control excluded Only case control	Control type	Tags	OR 95%CI	x1/n1 x0/n0	no cases	no exposed	ROB	Ref.
S12831 R48322	Thomas (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2021	Cardiac malformations	1st trimester	prospective cohort	exposed to other treatment, sick excluded	Adjustment: No	2.16 [0.22;21.41] ^C excluded (control group)	3/71 1/50	4	71		ref
S12833 R48334	Thomas (Oxcarbazepine) (Controls unexposed, sick), 2021	Cardiac malformations	1st trimester	prospective cohort	unexposed, sick	Adjustment: No	1.62 [0.43;6.15] ^C	3/71 9/340	12	71		ref
S9074 R31061	Tomson (Oxcarbazepine), 2018	Cardiac malformations	at least 1st trimester	prospective cohort	exposed to other treatment, sick	Adjustment: No	2.03 [0.67;6.14] ^C	4/333 15/2,514	19	333		ref
S9062 R30936	Morrow (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2006	Cardiac	1st trimester	prospective cohort	exposed to other treatment, sick	Adjustment: No	10.98 [0.53;225.56] ^C	0/7 4/647	4	7		ref
S9057 R30915	Artama (Oxcarbazepine), 2005	Cardiovascular	1st trimester	retrospective cohort (registry)	unexposed, sick	Adjustment: No	0.63 [0.04;11.12] ^C	0/99 7/939	7	99		ref
					Total	4 studies	1.93 [0.87;4.24]		42	510
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; ^C: calculated odds ratio from numbers of events and effectives

Forest plot

1: Oxcarbazepine) (Controls unexposed, sick; 2: Oxcarbazepine; 3: Oxcarbazepine) (Controls exposed to Lamotrigine, sick; 4: Oxcarbazepine;

Sensitivity analysis

Publication bias and p-hacking diagnosis

funnel plot

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Sub-groups analysis using all included studies

excluded 12831